Edgewise Therapeutics Inc
EWTX13.170USD
+0.110+0.84%
收盤 06/27, 16:00（美東）報價延遲15分鐘
1.25B總市值
虧損本益比TTM
關於 Edgewise Therapeutics Inc 公司
Edgewise Therapeutics, Inc. 是一家肌肉疾病生物製藥公司，致力於開發治療肌營養不良症和嚴重心臟病的新型療法。該公司的主要候選產品 sevasemten (EDG-5506) 是一種口服骨骼肌球蛋白抑制劑，目前正在進行貝克爾和杜氏肌營養不良症的後期臨牀試驗。其 EDG-7500 是一種新型心臟肌節調節劑，用於治療肥厚性心肌病和其他舒張功能障礙疾病，目前處於 II 期臨牀開發階段。該公司正在利用其專有的藥物發現平臺開發一系列精準醫療候選產品，這些產品針對關鍵的肌肉蛋白和調節劑，以解決各種嚴重的肌肉疾病。其平臺利用定製的高通量和可轉化系統測量整個器官提取物中的綜合肌肉功能，以識別調節肌肉組織中關鍵蛋白質的小分子精準藥物。
公司簡介
公司代碼EWTX
公司名稱Edgewise Therapeutics Inc
上市日期Mar 26, 2021
成立日期2017
CEODr. Kevin Koch, Ph.D.
員工數量110
證券類型Ordinary Share
年結日Mar 26
公司地址1715 38Th St
城市BOULDER
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編80301
電話17202627002
網址https://edgewisetx.com/
公司代碼EWTX
上市日期Mar 26, 2021
成立日期2017
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Kevin Koch, Ph.D.
Dr. Kevin Koch, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
359.40K
+1.74%
Dr. Joanne M. Donovan, M.D., Ph.D.
Dr. Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
21.49K
+32.17%
Dr. Behrad Derakhshan, Ph.D.
Dr. Behrad Derakhshan, Ph.D.
Chief Operating Officer
Chief Operating Officer
20.36K
+20.89%
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
19.82K
--
Dr. Jonathan D. (Jon) Root, M.D.
Dr. Jonathan D. (Jon) Root, M.D.
Independent Director
Independent Director
15.63K
--
Dr. Jonathan C. Fox, M.D., Ph.D.
Dr. Jonathan C. Fox, M.D., Ph.D.
Independent Director
Independent Director
11.42K
+5.15%
Mr. John R. Moore
Mr. John R. Moore
General Counsel
General Counsel
1.34K
--
Dr. Alan Russell, Ph.D.
Dr. Alan Russell, Ph.D.
Chief Scientific Officer, Director, Co-Founder
Chief Scientific Officer, Director, Co-Founder
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Kevin Koch, Ph.D.
Dr. Kevin Koch, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
359.40K
+1.74%
Dr. Joanne M. Donovan, M.D., Ph.D.
Dr. Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
21.49K
+32.17%
Dr. Behrad Derakhshan, Ph.D.
Dr. Behrad Derakhshan, Ph.D.
Chief Operating Officer
Chief Operating Officer
20.36K
+20.89%
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
19.82K
--
Dr. Jonathan D. (Jon) Root, M.D.
Dr. Jonathan D. (Jon) Root, M.D.
Independent Director
Independent Director
15.63K
--
Dr. Jonathan C. Fox, M.D., Ph.D.
Dr. Jonathan C. Fox, M.D., Ph.D.
Independent Director
Independent Director
11.42K
+5.15%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
OrbiMed Advisors, LLC
14.50%
RA Capital Management, LP
8.47%
Perceptive Advisors LLC
6.22%
Baker Bros. Advisors LP
5.85%
BlackRock Institutional Trust Company, N.A.
5.13%
Other
59.83%
持股股東
持股股東
佔比
OrbiMed Advisors, LLC
14.50%
RA Capital Management, LP
8.47%
Perceptive Advisors LLC
6.22%
Baker Bros. Advisors LP
5.85%
BlackRock Institutional Trust Company, N.A.
5.13%
Other
59.83%
股東類型
持股股東
佔比
Hedge Fund
25.70%
Investment Advisor/Hedge Fund
22.72%
Private Equity
21.28%
Investment Advisor
15.06%
Venture Capital
14.86%
Research Firm
1.38%
Individual Investor
0.50%
Pension Fund
0.21%
Bank and Trust
0.16%
機構持股
更新時間: 2月24日 週一
更新時間: 2月24日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
379
105.11M
110.49%
-2.65M
2024Q4
367
101.45M
106.62%
-4.12M
2024Q3
338
103.17M
110.02%
-3.61M
2024Q2
297
103.29M
110.57%
-1.75M
2024Q1
271
99.64M
106.68%
+5.45M
2023Q4
244
81.22M
115.32%
+5.36M
2023Q3
218
69.97M
110.26%
-9.47M
2023Q2
215
71.14M
112.43%
-5.61M
2023Q1
210
68.18M
108.02%
-8.97M
2022Q4
198
68.18M
108.11%
-5.86M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
OrbiMed Advisors, LLC
15.02M
15.86%
--
--
Dec 31, 2024
RA Capital Management, LP
8.91M
8.5%
--
--
Dec 31, 2024
Perceptive Advisors LLC
5.16M
4.93%
+2.48M
+92.31%
Feb 13, 2025
Baker Bros. Advisors LP
6.16M
5.88%
+315.88K
+5.41%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.36M
5.12%
+9.02K
+0.17%
Dec 31, 2024
Novo Holdings A/S
5.00M
4.77%
-549.90K
-9.91%
Dec 31, 2024
Janus Henderson Investors
4.98M
4.76%
+425.42K
+9.33%
Dec 31, 2024
Paradigm BioCapital Advisors LP
4.74M
4.52%
+245.00K
+5.45%
Jan 27, 2025
The Vanguard Group, Inc.
4.46M
4.25%
-49.21K
-1.09%
Dec 31, 2024
Cormorant Asset Management, LP
3.41M
3.25%
--
--
Dec 31, 2024
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
2.21%
SPDR S&P Pharmaceuticals ETF
2.03%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.61%
ALPS Medical Breakthroughs ETF
1.12%
iShares U.S. Pharmaceuticals ETF
0.42%
Virtus LifeSci Biotech Clinical Trials ETF
0.38%
Federated Hermes MDT Small Cap Core ETF
0.34%
First Trust Multi-Manager Small Cap Opportunities ETF
0.18%
iShares Health Innovation Active ETF
0.17%
Invesco Nasdaq Biotechnology ETF
0.14%
查看更多
iShares Neuroscience and Healthcare ETF
佔比2.21%
SPDR S&P Pharmaceuticals ETF
佔比2.03%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比1.61%
ALPS Medical Breakthroughs ETF
佔比1.12%
iShares U.S. Pharmaceuticals ETF
佔比0.42%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.38%
Federated Hermes MDT Small Cap Core ETF
佔比0.34%
First Trust Multi-Manager Small Cap Opportunities ETF
佔比0.18%
iShares Health Innovation Active ETF
佔比0.17%
Invesco Nasdaq Biotechnology ETF
佔比0.14%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
